Mechanisms of Action of Antiestrogens: Relevance to Clinical Benefits and Risks

References

• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1–15; 71–85
   PubMed Web of Science ®Google Scholar
• Butta A, MacLennan K, Flanders K C. Induction of transforming growth factor bl in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261–4264
   PubMed Web of Science ®Google Scholar
• Pollak M N, Huynh H T, Lefebvre S P. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 1992; 22: 91–100
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88: 1529–1542
   PubMed Web of Science ®Google Scholar
• Love R R, Barden H S, Mazess R B. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994; 154: 2585–2588
   PubMed Web of Science ®Google Scholar
• Love R R, Wiebe D A, Feyzi J M. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534–1539
   PubMed Web of Science ®Google Scholar
• Barakat R R. The effect of tamoxifen on the endometrium. Oncology 1995; 9: 129–134
   PubMedGoogle Scholar
• Malet C, Gompel A, Spritzer P. Tamoxifen and hydroxyta-moxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res 1988; 48: 7193–7199
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 1995; 35: 195–211
   PubMed Web of Science ®Google Scholar
• Metzger D, Berry M, Chambon P. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol Endocrinol 1995; 9: 579–591
   PubMed Web of Science ®Google Scholar
• Webster N J, Green S, Jin J R, Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988; 54: 199–207
   PubMed Web of Science ®Google Scholar
• Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990; 9: 2811–2818
   PubMed Web of Science ®Google Scholar
• McInemey E M, Katzenellenbogen B S. Different regions in activation function-1 of the human estrogen receptor required for anti-estrogen- and estradiol-dependent transcription activation. J Biol Chem 1996; 271: 24172–24178
   PubMed Web of Science ®Google Scholar
• Smith C L, Nawaz Z, O'Malley B W. Coactivator and corepressor regulation of the agonistlantagonist activity of the mixed antiestrogen, Chydroxytamoxifen. Mol Endocrinol 1997; 11: 657–666
   PubMed Web of Science ®Google Scholar
• Majeska R J, Ryaby J T, Einhom T A. Direct modulation of osteoblastic activity with estrogen. J Bone Joint Surg Am 1994; 76: 713–721
   PubMed Web of Science ®Google Scholar
• Verhaar H J, Damen C A, Duursma S A, Scheven B A. A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone 1994; 15: 307–311, 1994
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Tokin M, Nagata K. Tamoxifen directly stimulates the mineralization of human osteoblast-like osteosarcoma cells through a pathway independent of estrogen response element. Biochem Biophys Res Commun 1995; 210: 295–301
   PubMed Web of Science ®Google Scholar
• Langdahl B L, Brixen K, Jensen H K. Mutations in the TGF-beta-1 gene are correlated to low bone mass and increased bone turnover. J Bone Miner Res 1995; 10: 185, (abstract)
   Google Scholar
• Hughes D E, Dai A, Tiffee J C. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996; 2: 1132–1136
   PubMed Web of Science ®Google Scholar
• Grainger D J, Kemp P R, Liu A C. Activation of transforming growth factor b is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460–462
   PubMed Web of Science ®Google Scholar
• Grainger D J, Metcalfe J C. Tamoxifen: teaching an old drug new tricks. Nat Med 1996; 2: 381–385
   PubMed Web of Science ®Google Scholar
• Ismail S M. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994; 47: 827–833
   PubMed Web of Science ®Google Scholar
• Cohen C. Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Semin Oncol 1977; 24: S55–S64, Suppl 1
   Google Scholar
• International Agency for Research on Cancer, World Health Organization. Monograph 66. IARC, LyonFrance 1996
   Google Scholar
• Gottardis M M, Robinson S P, Satyaswaroop P G, Jordan V C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48: 812–815
   PubMed Web of Science ®Google Scholar
• Magriples U, Naftolin F, Swartz P E. High-grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 1993; 11: 485–490
   PubMed Web of Science ®Google Scholar
• Jordan V C, Assikis V J. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1995; 1: 467–472
   PubMed Web of Science ®Google Scholar
• Neven P, Vergote I. Controversies regarding tamoxifen and uterine carcinoma. Curr Opin Obstet Gynecol 1998; 10: 9–14
   PubMed Web of Science ®Google Scholar
• Greaves P, Goonetilleke R, Nunn G. Two-year carcinogenic-ity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993; 53: 3919–3924
   PubMed Web of Science ®Google Scholar
• White I NH, De Matteis F, Davies A. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA12 and C57B116 mice and in human MCL-5 cells. Carcinogenesis 1992; 13: 2197–2203
   PubMed Web of Science ®Google Scholar
• Vancutsem P M, Lazarus P, Williams G M. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 1994; 54: 3864–3867
   PubMed Web of Science ®Google Scholar
• Anonymous. IARC on tamoxifen. Environ Health Perspect 1996; 104: 688
   PubMed Web of Science ®Google Scholar
• Carmichael P L, Ugwumadu A HN, Neven P. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996; 56: 1474–1479
   Google Scholar
• Hemminki K, Rajaniemi H, Lindahl B, Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 1996; 56: 4374–4377
   PubMed Web of Science ®Google Scholar
• White I NH, Davies A M, Gibbs A H. Comparison of the potential of microsomal fractions from human and rat reproductive tracts to activate tamoxifen. Proc Am Assoc Cancer Res 1997; 38: 337
   Google Scholar
• Rowlands M G, Budworth J, Jarman M. Comparison between inhibition of protein kinase C and antagonism of calmodu-lin by tamoxifen analogues. Biochem Pharmacol 1995; 50: 723–726
   PubMed Web of Science ®Google Scholar
• Ehring G R, Osipchuk Y V, Cahalan M D. Swelling-activated chloride channels in multidrug-sensitive and -resistant cells. J Gen Physiol 1994; 104: 1129–1161
   PubMed Web of Science ®Google Scholar
• Cox D A. Transforming growth factor-beta 3. Cell Biol Int 1995; 19: 357–371
   PubMed Web of Science ®Google Scholar
• Chegini N, Zhao Y, Williams R S, Flanders K C. Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology 1994; 135: 439–449
   PubMed Web of Science ®Google Scholar
• Markowitz S, Wang J, Myeroff L. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336–1338
   PubMed Web of Science ®Google Scholar
• Knabbe C, Lippman M E, Wakefield L M. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417–428
   PubMed Web of Science ®Google Scholar
• Jordan V C. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 1995; 35: 195–211
   PubMed Web of Science ®Google Scholar
• Dumont J A, Bitonti A J, Wallace C D. Progression of MCF-7 breast cancer cells to antoestrogen-resistant phenotype is accompanied by elevated levls of AP-I DNA-binding activity. Cell Growth Differ 1996; 7: 351–359
   PubMedGoogle Scholar
• Osborne C K, Coronado E B, Robinson J P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987; 23: 1189–1196
   PubMedGoogle Scholar
• Gottardis M M, Jordan V C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988; 48: 5183–5187
   PubMed Web of Science ®Google Scholar
• Howell A, DeFriend D, Robertson J. Response to a specific anti-estrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29–30
   PubMed Web of Science ®Google Scholar
• Hard G C, Iatropoulos M J, Jordan K. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993; 53: 4534–4541
   PubMed Web of Science ®Google Scholar
• Kangas L. Introduction to toremifene. Breast Cancer Res Treat 1990; 16: S3–S7, Suppl
   PubMed Web of Science ®Google Scholar
• Hayes D F, Van ZyI JA, Hacking A. Randomized comparison of tamoxifen and two separate doses of toremifene in postmeno-pausal patients with metastatic breast cancer. J Clin Oncol 1996; 13: 2556–2566
   Web of Science ®Google Scholar
• Vogel C L, Shemano I, Schoenfelder J. Multicenter Phase II efficacy trial of toremifene in tarnoxifen-refractory patients with advanced breast cancer. J Clin Oncol 1993; 11: 345–350
   PubMed Web of Science ®Google Scholar
• Rauschning W, Pritchard K I. Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat 1994; 31: 83–94
   PubMed Web of Science ®Google Scholar
• Buzdar A U, Kau S, Hortobagyi G N. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1994; 33: 313–316
   PubMed Web of Science ®Google Scholar
• Coombes R C, Haynes B P, Dowsett M. Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995; 55: 1070–1074
   PubMed Web of Science ®Google Scholar